Equities

Neurosense Therapeutics Ltd

NRSN:NAQ

Neurosense Therapeutics Ltd

Actions
  • Price (USD)0.9598
  • Today's Change-0.030 / -3.06%
  • Shares traded82.06k
  • 1 Year change+84.65%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 18:55 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

  • Revenue in USD (TTM)0.00
  • Net income in USD-7.51m
  • Incorporated2017
  • Employees16.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Palatin Technologies, Inc.2.38m-32.35m17.87m30.00------7.50-1.98-1.980.1434-0.39320.3252----79,470.34-441.31-55.28---69.0895.90---1,357.06-1,359.14---------7.49-40.52-23.71--3.31--
Finch Therapeutics Group Inc0.00-14.17m18.39m18.00--1.29-----8.82-8.820.008.860.00-------25.20---28.80--------------0.00---87.57--34.80------
NanoViricides Inc0.00-9.45m18.55m7.00--1.85-----0.7579-0.75790.000.71880.00----0.00-69.61-43.88-76.92-46.26------------0.00------3.43--16.23--
MEI Pharma Inc0.00-46.60m18.66m28.00--0.7499-----6.99-6.990.003.730.00----0.00-72.25-21.09-79.28-23.99-------72.23----0.00--33.7667.75155.84---49.68--
Mira Pharmaceuticals Inc0.00-11.24m18.70m3.00--5.76-----0.7287-0.72870.000.21970.00----0.00-169.22---191.76-------------3.320.00-------69.77------
Kairos Pharma Ltd0.00-2.74m18.75m----5.63-----0.2279-0.22790.000.25940.00-------92.10---264.70-------------2.610.0409-------72.57------
Neurosense Therapeutics Ltd0.00-7.51m19.28m16.00---------0.4392-0.43920.00-0.09430.00----0.00-154.72---470.03----------------------18.10------
Unity Biotechnology Inc0.00-19.05m19.71m19.00--1.39-----1.14-1.140.000.83940.00----0.00-32.73-47.21-38.49-53.51-------6,395.92----0.00---100.00--10.36---61.28--
Forte Biosciences Inc0.00-34.20m19.79m11.00--2.11-----20.00-20.000.006.420.00----0.00-103.90-72.06-137.40-82.27-------491,850.00----0.00-------126.79---46.29--
Goldenwell Biotech Inc940.00-137.11k19.80m----5,169.71--21,063.83-0.0014-0.00140.000010.000040.00480.0031-----69.82---70.29--42.55---14,586.17--21.43--0.00---95.10--88.13------
Ibio Inc175.00k-14.36m20.01m16.00--1.07--114.35-3.97-6.650.03072.060.0056----10,937.50-46.17-27.69-75.53-33.13-----8,204.57-1,862.11----0.0736-----35.5247.31---26.66--
OpGen Inc1.96m-22.39m20.04m100.00------10.20-20.01-20.011.66-8.650.1553--6.09---176.99-87.95-15,455.17-127.653.1515.42-1,139.66-794.78---20.25----31.113.0212.38--40.20--
Spruce Biosciences Inc7.10m-39.43m20.24m22.00--0.3919--2.85-0.9598-0.95980.17281.250.0798----244,862.10-44.28-41.24-55.51-46.49-----555.23-1,774.39---121.120.0399-------3.77------
Pulmatrix Inc10.01m-9.66m20.53m22.00--1.88--2.05-2.64-2.642.742.990.4145--23.16454,772.70-40.00-46.91-44.64-58.12-----96.51-238.04----0.00--20.21116.6225.03--104.29--
Neurobo Pharmaceuticals Inc0.00-27.73m20.68m8.00--1.60-----4.77-4.770.001.500.00----0.00-114.20-95.57-159.68-135.64------------0.00------10.72--75.54--
Data as of Nov 21 2024. Currency figures normalised to Neurosense Therapeutics Ltd's reporting currency: US Dollar USD

Institutional shareholders

1.16%Per cent of shares held by top holders
HolderShares% Held
Cantor Fitzgerald Europeas of 30 Sep 202479.49k0.41%
XTX Markets LLCas of 30 Sep 202446.00k0.24%
Meitav Mutual Funds Ltd.as of 30 Sep 202440.00k0.21%
Citadel Securities LLCas of 30 Sep 202434.28k0.18%
Commonwealth Equity Services LLCas of 30 Sep 202412.63k0.07%
Geode Capital Management LLCas of 30 Sep 202411.96k0.06%
CWM LLCas of 30 Sep 20241.00k0.01%
Armistice Capital LLCas of 30 Sep 20240.000.00%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 20240.000.00%
Schiketanz Capital Advisors GmbHas of 28 Jun 20240.000.00%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.